Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @genentech
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @genentech
-
We were named one of the
@BestWorkplaces for Commuters! One of our 2020 sustainability goals is to reduce CO2 emissions from transportation activities by 10%. Learn more about our efforts to create an environmentally sustainable future: http://bit.ly/2OelwAT#BWC2020pic.twitter.com/mZE8zas2uJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This National
#MentoringMonth, learn how more than 1,300 of our employees volunteer their time as mentors to inspire the next generation of scientists, innovators and critical thinkers. http://bit.ly/2t4Qa8B pic.twitter.com/QGTHj6Ykad
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Check out our new study in
@CellReports from Jason Hackney and colleagues which identifies causal genes for age-related macular degeneration, a leading cause of vision loss.http://bit.ly/310awMVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ICYMI: The
@US_FDA is reviewing our#immunotherapy combination for the most common type of#livercancer under its Real-Time Oncology Review pilot program. Learn more:http://bit.ly/37DvgfKHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're proud to help support this important research initiative around
#healthequity in clinical trials with our partner@SU2C!#advancinginclusiveresearchhttps://twitter.com/SU2Cscience/status/1221842022526439424 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Is it possible to extend human health? Check out the final
#podcast episode of Season 3 to learn how we might be able to engage our body's own repair mechanisms to delay the onset of age-related disease.http://bit.ly/37v4ypCHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Breaking: Our#immunotherapy combination for the most common type of#livercancer is being reviewed under the@US_FDA Real-Time Oncology Review pilot program, which aims to get treatments to patients faster.https://www.gene.com/media/press-releases/14835/2020-01-26/genentech-submits-supplemental-biologics …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we shared an update on our Phase III study evaluating our immunotherapy for a specific type of bladder cancer. Learn more:https://www.gene.com/media/press-releases/14834/2020-01-23/genentech-provides-an-update-on-phase-ii …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Breaking: Pivotal trial evaluating our spinal muscular atrophy (#SMA) medicine meets primary endpoint in infants with Type 1#SMAhttps://www.gene.com/media/press-releases/14833/2020-01-22/genentechs-risdiplam-meets-primary-endpo …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Genentech proslijedio/la je Tweet
“We are going after multiple TCRs against multiple targets simultaneously...that’s why we’re excited about this strategy” - CSO Harlan Robins, with
@genentech VP, Cancer Immunology, Ira Mellman at#PMWC20 Learn more about our partnership: http://rebrand.ly/xr7dp3 pic.twitter.com/HBrqXckCtR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Genentech proslijedio/la je Tweet
Cancer mutations create neoantigens that are of great interest for immunotherapy, but their accurate identification remains a challenge.
@genentech researchers show that mutation position is an important determinant for immunogenicity https://bit.ly/2Nwtd5l@jamescev19@jsuchitpic.twitter.com/WAS3l1m3Ew
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Genentech proslijedio/la je Tweet
Join co-founder & Chief Scientific Officer, Harlan Robins, and
@genentech Vice President, Cancer Immunology, Ira Mellman at#PMWC20 for a fireside chat on progress, challenges, and what’s next for cancer immunotherapy. Read more about our partnership: https://rebrand.ly/xr7dp3 pic.twitter.com/ExPsWpLzm2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Tomorrow at
#PMWC20, Ira Mellman, Vice President, Cancer Immunology, joins@AdaptiveBiotech Co-founder & Chief Scientific Officer, Harlan Robins, for a fireside chat on cancer immunotherapy. Read more about our partnership with Adaptive.http://bit.ly/37fqoxrHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re honored to be named one of
@Forbes Best Employers for Diversity! Learn how we’re fostering a culture where difference is valued and celebrated: http://bit.ly/2TLvqO4 pic.twitter.com/CsCQYOUIfm
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Neoantigens result from cancer-specific genetic mutations. In
@JExpMed, a team led by Aude-Hélène Capietto, Suchit Jhunjhunwala & Lélia Delamarre identify traits of these mutations that could help prioritize targets for future cancer#immunotherapies. http://bit.ly/30wjsJFHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Looking for in-flight entertainment on your way home from
#JPM20? Tune in to our latest#podcast episode to hear from Mark Lee and David Shames about how#bigdata could help deliver personalized care to those who need it.http://bit.ly/2QYvisSHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
DYK that of the nearly 4,000 “druggable” targets known today, only about a quarter have been drugged or have a medicine that can impact them? See how we’re working to address this long-standing challenge with our partners.
#JPM20http://bit.ly/2TtNzjmHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Solving the challenges facing the healthcare industry is best tackled as a team. That’s why we have 220 ongoing
#collaborations around the world. Learn more about our continued commitment to#partnering.#JPM20http://bit.ly/2QXkk75Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
No single institution can change anything as sophisticated and complex as healthcare. See how our partnerships are helping to usher in a new age of
#personalizedhealthcare.#JPM20http://bit.ly/2tkDt9RHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congrats to Dr. Sandra Horning for being selected as
@HBAnet's Woman of the Year! We're thankful for her incredible contributions to medicine & to our employees who have been inspired by her commitment to science, patients & women in leadership. http://bit.ly/36VXKkv#HBAWOTY20pic.twitter.com/8AMroK4r5l
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.